Sabby Management, LLC Aeterna Zentaris Inc. Transaction History

Sabby Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$0.59 - $0.88 $144,101 - $214,931	-244,240 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$0.83 - $1.14 $293,987 - $403,790	-354,202 Reduced 59.19%	244,240 $214,000
Q1 2021 May 17, 2021	BUY	$0.51 - $3.34 $305,205 - $2 Million	598,442 New	598,442 $682,000
Q1 2020 May 15, 2020	SELL	$0.42 - $1.44 $42,829 - $146,845	-101,976 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.77 - $1.08 $23,023 - $32,292	29,900 Added 41.48%	101,976 $93,000
Q3 2019 Nov 15, 2019	BUY	$1.0 - $2.97 $59,277 - $176,052	59,277 Added 463.14%	72,076 $74,000
Q2 2019 Aug 14, 2019	BUY	$2.04 - $5.43 $26,109 - $69,498	12,799 New	12,799 $38,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.